393 related articles for article (PubMed ID: 26209551)
21. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
[TBL] [Abstract][Full Text] [Related]
22. Myeloproliferative neoplasm stem cells.
Mead AJ; Mullally A
Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
[TBL] [Abstract][Full Text] [Related]
23. Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.
Patterson-Fortin J; Moliterno AR
Curr Hematol Malig Rep; 2017 Oct; 12(5):424-431. PubMed ID: 28948454
[TBL] [Abstract][Full Text] [Related]
24. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
25. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
26. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
27. Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.
Zhang SJ; Abdel-Wahab O
Curr Hematol Malig Rep; 2012 Mar; 7(1):34-42. PubMed ID: 22170482
[TBL] [Abstract][Full Text] [Related]
28. Familial MPN Predisposition.
Tashi T; Swierczek S; Prchal JT
Curr Hematol Malig Rep; 2017 Oct; 12(5):442-447. PubMed ID: 29027642
[TBL] [Abstract][Full Text] [Related]
29. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
30. A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms.
Mambet C; Matei L; Necula LG; Diaconu CC
J Immunoassay Immunochem; 2016; 37(4):331-45. PubMed ID: 26890068
[TBL] [Abstract][Full Text] [Related]
31. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.
Magor GW; Tallack MR; Klose NM; Taylor D; Korbie D; Mollee P; Trau M; Perkins AC
J Mol Diagn; 2016 Sep; 18(5):707-718. PubMed ID: 27449473
[TBL] [Abstract][Full Text] [Related]
32. [Application of genetic data to clinical practice of MPN].
Edahiro Y
Rinsho Ketsueki; 2015 Aug; 56(8):949-55. PubMed ID: 26345552
[TBL] [Abstract][Full Text] [Related]
33. Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications.
Morsia E; Torre E; Poloni A; Olivieri A; Rupoli S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562964
[TBL] [Abstract][Full Text] [Related]
34. Molecular diagnostic criteria of myeloproliferative neoplasms.
Andrews C; Conneally E; Langabeer SE
Expert Rev Mol Diagn; 2023; 23(12):1077-1090. PubMed ID: 37999991
[TBL] [Abstract][Full Text] [Related]
35. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms.
Wang JC; Chen C; Kundra A; Kodali S; Pandey A; Wong C; Cheung T; Gotlieb V; Joseph G; Tribie S
Leuk Res; 2019 Apr; 79():52-59. PubMed ID: 30851544
[TBL] [Abstract][Full Text] [Related]
36. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
Front Immunol; 2020; 11():604142. PubMed ID: 33329600
[TBL] [Abstract][Full Text] [Related]
37. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
38. Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms.
Loscocco GG; Coltro G; Guglielmelli P; Vannucchi AM
Cells; 2021 Aug; 10(8):. PubMed ID: 34440731
[TBL] [Abstract][Full Text] [Related]
39. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
40. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
